Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study.

COVID-19 SARS-CoV-2 Salamanca Spain antibodies screening seroprevalence university

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
21 Jul 2021
Historique:
received: 17 05 2021
revised: 10 07 2021
accepted: 15 07 2021
entrez: 7 8 2021
pubmed: 8 8 2021
medline: 8 8 2021
Statut: epublish

Résumé

Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called "DIANCUSAL" (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July-October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties ( The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.

Sections du résumé

BACKGROUND BACKGROUND
Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called "DIANCUSAL" (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial.
OBJECTIVE OBJECTIVE
The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity.
METHODOLOGY METHODS
The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July-October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM.
PRINCIPAL FINDINGS RESULTS
A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (
CONCLUSIONS CONCLUSIONS
The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.

Identifiants

pubmed: 34361998
pii: jcm10153214
doi: 10.3390/jcm10153214
pmc: PMC8348112
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Commun. 2020 Nov 12;11(1):5744
pubmed: 33184284
Eur J Immunol. 2020 Dec;50(12):2025-2040
pubmed: 33084029
Life (Basel). 2020 Sep 21;10(9):
pubmed: 32967110
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669412
Eur Eat Disord Rev. 2020 Nov;28(6):799-815
pubmed: 32974994
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
EXCLI J. 2021 Feb 09;20:276-280
pubmed: 33628163
J Clin Lab Anal. 2020 Oct;34(10):e23466
pubmed: 32671890
Science. 2021 Feb 19;371(6531):
pubmed: 33323424
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1258-1264
pubmed: 32915165
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
Respir Med. 2021 Jan;176:106237
pubmed: 33246296
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Diabetes Metab Res Rev. 2021 Feb;37(2):e3377
pubmed: 32588943
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Adolesc Health. 2020 Dec;67(6):763-768
pubmed: 33071164
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Diagnostics (Basel). 2020 May 19;10(5):
pubmed: 32438677

Auteurs

Antonio Muro (A)

Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain.

Moncef Belhassen-García (M)

Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain.

Juan Luís Muñoz Bellido (JL)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain.
Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain.

Helena Lorenzo Juanes (H)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain.
Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain.

Belén Vicente (B)

Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain.

Josué Pendones (J)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain.
Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain.

José Adserias (J)

IT Department, University of Salamanca Foundation (FGUSAL), University of Salamanca, 37008 Salamanca, Spain.

Gonzalo Sánchez Hernández (G)

Data Processing Center (CPD), University of Salamanca, 37008 Salamanca, Spain.

Miguel Rodríguez Rosa (M)

Department of Statistics, University of Salamanca, 37008 Salamanca, Spain.

José Luis Vicente Villardón (JL)

Department of Statistics, University of Salamanca, 37008 Salamanca, Spain.

Javier Burguillo (J)

Department of Chemistry-Physics, Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain.

Javier López Andaluz (J)

Department of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, Spain.

Jose Angel Martín Oterino (JA)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Department of Internal Medicine, Faculty of Medicine, University Hospital of Salamanca, 37008 Salamanca, Spain.

Francisco Javier García Criado (FJ)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.

Fausto Barbero (F)

Department of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, Spain.

Ana Isabel Morales (AI)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Toxicology Unit, University of Salamanca, 37008 Salamanca, Spain.

Purificación Galindo Villardón (P)

Department of Statistics, University of Salamanca, 37008 Salamanca, Spain.

Rogelio González Sarmiento (R)

Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain.
Molecular Medicine Unit, Department of Medicine, University of Salamanca, 37008 Salamanca, Spain.

Classifications MeSH